O’Connor K, Walsh JC, Schaeffer DF

Language: English
References: 25
Page: 317-322
PDF size: 155.77 Kb.

ABSTRACT

Patients with hepatocellular carcinoma (HCC), the fifth most common cancer worldwide, display a highly variable clinical course, suggesting that HCC encompasses several biologically distinct subtypes. This heterogeneity has the potential to impede both treatment decisions and prognostic predictions for patients with HCC. One distinct, albeit rare, subtype of HCC is combined hepatocellular-cholangiocarcinoma (cHCC-CC), which overall carries a poorer prognosis than HCC and cholangiocarcinoma (CC) alone. This review discusses predominantly the histopathologic and pathogenetic intricacies of this tumor and highlights the need for an accurate diagnosis of this specific HCC subtype.

REFERENCES

1. Goodman ZD, Ishak KG, Langloss JM, Sesterhenn IA, Rabin L. Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. Cancer 1985; 55: 124-35.

2. Theise ND, Nakashima O, Park YN, Nakanuma Y. Combined hepatocellular-cholangiocarcinoma. Bosman FT, Carneiro F, Hruban RH, Theise ND (ed.). WHO classification of tumours of the digestive system. Lyon, France: IARC Press; 2010, p. 225-7.

3. Wachtel MS, Zhang Y, Xu T, Chiriva-Internati M, Frezza EE. Combined hepatocellular cholangiocarcinomas; analysis of a large database. Clin Med Pathol 2008; 1: 43-7.

4. Curado MP, Edwards B, Shin HR, Ferlay J, Heanue M, Boyle P, Storm H. Cancer incidence in five continents. Lyon France: IARC Press; 2007.

5. Ng IO, Shek TW, Nicholls J, Ma LT. Combined hepatocellular- cholangiocarcinoma: a clinicopathologic study. J Gastroenterol Hepatol 1998; 13: 34-40.

6. Yano Y, Yamamoto J, Kosuge T, Sakamoto Y, Yamasaki S, Shimada K, Ojima H, et al. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Jpn J Clin Oncol 2003; 33: 283-7.

7. Jarnagin WR, Weber S, Tickoo SK, Koea JB, Obiekwe S, Fong Y, DeMatteo RP, et al. Combined hepatocellular and cholangiocarcinoma: demographic, clinical and prognostic factors. Cancer 2002; 94: 2040-6.

8. Komuta M, Spee B, Vander Borght S, DeRos R, Verslype C, Aerts R, Yano H, et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology 2008; 47: 1544-56.

9. Fujii H, Zhu XG, Matsumoto T, Inagaki M, Tokusashi Y, Miyokawa N, Fukusato T et al. Genetic classification of combined hepatocellular-cholangiocarcinoma. Hum Pathol 2000; 31: 1011-7.

10. Imai Y, Oda H, Arai M, Shimizu S, Nakatsuru Y, Inoue T, Ishikowa T. Mutational analysis of the p53 and K-ras Genes and Allelotype Study of the Rb-1 Gene for investigating the Pathogenesis of Combined Hepatocellular-Cholangio-cellular Carcinomas. Jpn J Cancer Res 1996; 87: 1056-62.

11. Kassahun WT, Hauss J. Management of combined hepatocellular and cholangiocarcinoma. Int J Clin Pract 2008; 62: 1271-8.

12. Fowler KJ, Sheybani A, Parker RA 3rd, Doherty SM, Brunt E, Chapman WC, Menias CO. Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: imaging features and diagnostic accuracy of contrast-enhanced CT and MRI. AJR Am J Roentgenol 2013; 201: 332-9.

13. Sanada Y, Shiozaki S, Aoki H, Takakura N, Yoshida K, Yamaguchi Y. A clinical study of 11 cases of combined hepatocellular- cholangiocarcinoma. Assessment of enhancement patterns on dynamics computed tomography before resection. Hepatol Res 2005; 32: 185-95.

14. Fukukura Y, Taguchi J, Nakashima O, Wada Y, Kojiro M. Combined hepatocellular and cholangiocarcinoma: correlation between CT findings and clinicopathological features. J Comput Assist Tomogr 1997; 21: 52-8.

15. Tickoo SK, Zee SY, Obiekwe S, Xiao H, Koea J, Robiou C, Blumgart LH, et al. Combined hepatocel-lular-cholangiocarcinoma: a histopathologic, immunohistochemical, and in situ hybridization study. Am J Surg Pathol 2002; 26: 989-97.

16. Krings G, Ramachandran R, Jain D, Wu TT, Yeh MM, Torbenson M, Kakar S. Immunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma. Mod Pathol 2013; 26: 782-91.

17. Kim H, Park C, Han KH, Choi J, Kim YB, Kim JK, Park YN. Primary liver carcinoma of intermediate (hepatocytecholangiocyte) phenotype. J Hepatol 2004; 40: 298-304.

18. Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 2006; 25: 3818-22.

19. Theise ND, Yao JL, Harada K, Hytiroglou P, Portmann B, Thung SN, Tsui W, et al. Hepatic ‘stem cell’ malignancies in adults: four cases. Histopathology 2003; 43: 263-71.

20. Lee JH, Chung G, Yu S, Hwang SY, Kim JS, Kim HY, Yoon JH, et al. Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma. J Clin Gastroenterol 2011; 45: 69-75.

21. Yin X, Zhang BH, Qiu SJ, Ren ZG, Zhou J, Chen XH, Zhou Y, et al. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol 2012; 19: 2869-76.

22. Sapisochin G, Fidelman N, Roberts JP, Yao FY. Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma. Liver Transplant 2011; 17: 934-42.

23. Yamashita T, Wang XW. Cancer stem cells in the development of liver cancer. J Clin Invest 2013; 123: 1911-8.

24. Chi M, Mikhitarian K, Shi C, Goff LW. Management of combined hepatocellular-cholangiocarcinoma: a case report and literature review. Gastrointest Cancer 2012; 5: 199- 202.

25. Kim GM, Jeung HC, Kim D, Kim JH, Yoon SH, Jung ES, Shin SJ. A case of combined hepatocellular-cholangiocarcinoma with favourable response to systemic chemotherapy. Cancer Res Treat 2010; 42: 235-8.